Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum

Journal of Molecular Neuroscience

Volumn 25, Issue 1, 2005, Pages 29-36

  Stonehouse, Anthony H ^a,b   Jones, Frederick S ^a  

^a NEUROSCIENCES INSTITUTE   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Agonist; Antagonist; Bromocriptine mesylate; Clozapine; D2R luciferase reporter construct; Dopamine 2 receptor; Mouse striatum; PC12 cells; Quantitative RT PCR

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE MESILATE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LUCIFERASE; MESSENGER RNA; NEUROLEPTIC AGENT; SEROTONIN ANTAGONIST; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GENDER; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RAT; REGULATORY MECHANISM; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; ANIMAL; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

PARKINSONIA;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BROMOCRIPTINE; CLOZAPINE; CORPUS STRIATUM; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; MALE; MICE; PC12 CELLS; RATS; RECEPTORS, DOPAMINE D2;

EID: 25144460699     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:25:1:029     Document Type: Article

References (30)

1. Aizman O., Brismar H., Uhlen P., Zettergren E., Levey A. I., Forssberg H., et al. (2000) Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3, 226-230.
2. Al-Semaan Y. (1996) Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia. Can. J. Psychiatry 41, 484-485.
3. Al-Semaan Y. M., Clay H. A., and Meltzer H. Y. (1997) Clozapine in treatment of bromocriptine-induced psychosis. J. Clin. Psychopharmacol. 17, 126-128.
4. Arslan G., Kull B., and Fredholm B. B. (1999) Signaling via A2A adenosine receptor in four PC12 cell clones. Naunyn Schmiedebergs Arch. Pharmacol. 359, 28-32.
5. Ashby C. R. Jr. and Wang R. Y. (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349-394.
6. Carlsson A. (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11, 490-493.
7. Copertino D. W., Edelman G. M., and Jones F. S. (1997) Multiple promoter elements differentially regulate the expression of the mouse tenascin gene. Proc. Natl. Acad. Sci. U. S. A. 94, 1846-1851.
8. Dalla Libera A., Scutari G., Boscolo R., Rigobello M. P., and Bindoli A. (1998) Antioxidant properties of clozapine and related neuroleptics. Free Radic. Res. 29, 151-157.
9. Damask S. P., Bovenkerk K. A., de la Pena G., Hoversten K. M., Peters D. B., Valentine A. M., and Meador-Woodruff J. H. (1996) Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex. Brain Res. Mol. Brain Res. 41, 241-249.
10. Diaz-Cabiale Z., Hurd Y., Guidolin D., Finnman U. B., Zoli M., Agnati L. F., et al. (2001) Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. NeuroReport 12, 1831-1834.
11. D'Souza D. N., Harlan R. E., and Garcia M. M. (1999) Sexual dimorphism in the response to N-methyl-D-aspartate receptor antagonists and morphine on behavior and c-Fos induction in the rat brain. Neuroscience 93, 1539-1547.
12. D'Souza D. N., Harlan R. E., and Garcia M. M. (2002) Sexually dimorphic effects of morphine and MK-801: sex steroid-dependent and -independent mechanisms. J. Appl. Physiol. 92, 493-503.
13. Ferre S., von Euler G., Johansson B., Fredholm B. B., and Fuxe K. (1991) Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U. S. A. 88, 7238-7241.
14. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., et al. (2002) Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 1054-1062.
15. Fuxe K. and Ungerstedt U. (1974) Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 52, 48-54.
16. Gingrich J. A. and Caron M. G. (1993) Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16, 299-321.
17. Kartzinel R., Teychenne P., Gillespie M. M., Perlow M., Gielen A. C., Sadowsky D. A., and Calne D. B. (1976) Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 2, 272-275.
18. Kitamura Y., Taniguchi T., Shimohama S., Akaike A., and Nomura Y. (2003) Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem. Res. 28, 1035-1040.
19. Lewis D. A. and Lieberman J. A. (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325-334.
20. McGeer P. L., Itagaki S., Akiyama H., and McGeer E. G. (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24, 574-576.
21. Meltzer H. Y., Kennedy J., Dai J., Parsa M., and Riley D. (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 12, 39-45.
22. Orr G., Munitz H., and Hermesh H. (2001) Low-dose clozapine for the treatment of Parkinson's disease in a patient with schizophrenia. Clin. Neuropharmacol. 24, 117-119.
23. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., et al. (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 337, 809-815.
24. Schiffmann S. N. and Vanderhaeghen J. J. (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13, 1080-1087.
25. Silver H. (2003) Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int. Clin. Psychopharmacol. 18, 305-313.
26. Stonehouse A. H., Adachi M., Walcott E. C., and Jones F. S. (2003b) Caffeine regulates neuronal expression of the dopamine 2 receptor gene. Mol. Pharmacol. 64, 1463-1473.
27. Stoof J. C. and Kebabian J. W. (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 35, 2281-2296.
28. Svetel M. V., Sternic N. M., Filipovic S. R., Vojvodic N. M., and Kostic V. S. (1997) Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa. Srp. Arh. Celok. Lek. 125, 203-206.
29. VonVoigtlander P. F., Fici G. J., and Althaus J. S. (1998) Pharmacological approaches to counter the toxicity of Dopa. Amino Acids 14, 189-196.
30. Zhu W. H., Conforti L., and Millhorn D. E. (1997) Expression of dopamine D2 receptor in PC-12 cells and regulation of membrane conductances by dopamine. Am. J. Physiol 273, C1143-1150.